drugset / Trial / NCT05540951
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Non-randomizedParallel-groupSingle-blindTreatment
Summary
In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2022-08-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Vemurafenib | Small molecule | — | — |